Our most recent publications

Click here to view all research publications from the Translational Haematology lab

2024

Editorial: Multiple Myeloma: Molecular Mechanism and Targeted Therapy.

Bazou D, Dowling P.Int J Mol Sci. 2024 Mar 28;25(7):3799. doi: 10.3390/ijms25073799.PMID: 38612612

Multiple Myeloma Derived Extracellular Vesicle Uptake by Monocyte Cells Stimulates IL-6 and MMP-9 Secretion and Promotes Cancer Cell Migration and Proliferation.

Sheridan R, Brennan K, Bazou D, O'Gorman P, Matallanas D, Mc Gee MM.Cancers (Basel). 2024 Feb 29;16(5):1011. doi: 10.3390/cancers16051011.PMID: 38473370

2023

Bleeding and Thrombosis in Multiple Myeloma: Platelets as Key Players during Cell Interactions and Potential Use as Drug Delivery Systems.

Kulkarni A, Bazou D, Santos-Martinez MJ.Int J Mol Sci. 2023 Nov 1;24(21):15855. doi: 10.3390/ijms242115855.PMID: 37958838

Using Proteomics Data to Identify Personalized Treatments in Multiple Myeloma: A Machine Learning Approach.

Katsenou A, O'Farrell R, Dowling P, Heckman CA, O'Gorman P, Bazou D.Int J Mol Sci. 2023 Oct 25;24(21):15570. doi: 10.3390/ijms242115570.PMID: 37958554

Proteomic and Metabolomic Analysis of Bone Marrow and Plasma from Patients with Extramedullary Multiple Myeloma Identifies Distinct Protein and Metabolite Signatures.

Dunphy K, Bazou D, Henry M, Meleady P, Miettinen JJ, Heckman CA, Dowling P, O'Gorman P.Cancers (Basel). 2023 Jul 25;15(15):3764. doi: 10.3390/cancers15153764.PMID: 37568580

Analysis of Cancer Cell Line Secretomes: A Complementary Source of Disease-Specific Protein Biomarkers.

Dunphy K, Bazou D, Dowling P.Methods Mol Biol. 2023;2645:277-287. doi: 10.1007/978-1-0716-3056-3_18.PMID: 37202627

A Self-Assembly Method for Creating Vascularized Tumor Explants Using Biomaterials for 3D Culture.

Munn LL, Bazou D.Methods Mol Biol. 2023;2645:211-220. doi: 10.1007/978-1-0716-3056-3_12.PMID: 37202621

Inhibition of CXCR4 Enhances the Efficacy of Radiotherapy in Metastatic Prostate Cancer Models.

Gupta N, Ochiai H, Hoshino Y, Klein S, Zustin J, Ramjiawan RR, Kitahara S, Maimon N, Bazou D, Chiang S, Li S, Schanne DH, Jain RK, Munn LL, Huang P, Kozin SV, Duda DG.Cancers (Basel). 2023 Feb 6;15(4):1021. doi: 10.3390/cancers15041021.PMID: 36831366

Identification of Ubiquitination-Associated Proteins Using 2D-DIGE.

Dowling P, Bazou D.Methods Mol Biol. 2023;2596:83-96. doi: 10.1007/978-1-0716-2831-7_6.PMID: 36378432

2022

Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches.

Dowling P, Tierney C, Dunphy K, Miettinen JJ, Heckman CA, Bazou D, O'Gorman P.Proteomes. 2022 Oct 30;9(4):42. doi: 10.3390/proteomes9040042.PMID: 34842843

2021

S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma.

Liu M, Wang Y, Miettinen JJ, Kumari R, Majumder MM, Tierney C, Bazou D, Parsons A, Suvela M, Lievonen J, Silvennoinen R, Anttila P, Dowling P, O'Gorman P, Tang J, Heckman CA.Front Cell Dev Biol. 2021 Aug 16;9:723016. doi: 10.3389/fcell.2021.723016. eCollection 2021.PMID: 34485305

Clinical Proteomics of Biofluids in Haematological Malignancies.

Dunphy K, O'Mahoney K, Dowling P, O'Gorman P, Bazou D.Int J Mol Sci. 2021 Jul 27;22(15):8021. doi: 10.3390/ijms22158021.PMID: 34360786

Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients.

Tierney C, Bazou D, Majumder MM, Anttila P, Silvennoinen R, Heckman CA, Dowling P, O'Gorman P.Sci Rep. 2021 Jun 18;11(1):12866. doi: 10.1038/s41598-021-90149-y.PMID: 34145309

Current Methods of Post-Translational Modification Analysis and Their Applications in Blood Cancers.

Dunphy K, Dowling P, Bazou D, O'Gorman P.Cancers (Basel). 2021 Apr 16;13(8):1930. doi: 10.3390/cancers13081930.PMID: 33923680

Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen.

Miettinen JJ, Kumari R, Traustadottir GA, Huppunen ME, Sergeev P, Majumder MM, Schepsky A, Gudjonsson T, Lievonen J, Bazou D, Dowling P, O Gorman P, Slipicevic A, Anttila P, Silvennoinen R, Nupponen NN, Lehmann F, Heckman CA.Cancers (Basel). 2021 Mar 26;13(7):1527. doi: 10.3390/cancers13071527.PMID: 33810334

Successful treatment of solitary bone plasmacytoma and bone remineralisation with novel biological agents leading to new bone formation - a case series.

Blum A, Bazou D, Ting KR, Bianchi G, Mahandran M, Mahandran H, Eustace S, Richardson PG, O'Gorman P.Br J Haematol. 2021 May;193(4):e36-e38. doi: 10.1111/bjh.17413. Epub 2021 Mar 21.PMID: 33748981

Saliva-omics in plasma cell disorders- Proof of concept and potential as a non-invasive tool for monitoring disease burden.

Tierney C, Bazou D, Lê G, Dowling P, O'Gorman P.J Proteomics. 2021 Jan 16;231:104015. doi: 10.1016/j.jprot.2020.104015. Epub 2020 Oct 14.PMID: 33068749

2020

Marizomib: A novel therapeutic approach for the treatment of central nervous system myeloma.

Bazou D, Le G, Boyle A, Blum A, O'Gorman P.EJHaem. 2020 Aug 12;1(1):315-317. doi: 10.1002/jha2.72. eCollection 2020 Jul.PMID: 35847709

ALI multilayered co-cultures mimic biochemical mechanisms of the cancer cell-fibroblast cross-talk involved in NSCLC MultiDrug Resistance.

Movia D, Bazou D, Prina-Mello A.BMC Cancer. 2019 Aug 29;19(1):854. doi: 10.1186/s12885-019-6038-x.PMID: 31464606

Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types.

Majumder MM, Leppä AM, Hellesøy M, Dowling P, Malyutina A, Kopperud R, Bazou D, Andersson E, Parsons A, Tang J, Kallioniemi O, Mustjoki S, O'Gorman P, Wennerberg K, Porkka K, Gjertsen BT, Heckman CA.Haematologica. 2020 Jun;105(6):1527-1538. doi: 10.3324/haematol.2019.217414. Epub 2019 Aug 22.PMID: 31439679